Temozolomide Therapy for Aggressive Pituitary Tumors: Results in a Small Series of Patients from Argentina

We evaluated results of temozolomide (TMZ) therapy in six patients, aged 34–78 years, presenting aggressive pituitary tumors. In all the patients tested O(6)-methylguanine-DNA methyltransferase (MGMT) immunoexpression in surgical specimens was absent. Patients received temozolomide 140–320 mg/day fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Bruno, Oscar D., Juárez-Allen, Lea, Christiansen, Silvia B., Manavela, Marcos, Danilowicz, Karina, Vigovich, Carlos, Gómez, Reynaldo M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2015
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4461777/
https://www.ncbi.nlm.nih.gov/pubmed/26106414
http://dx.doi.org/10.1155/2015/587893

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4461777/
https://www.ncbi.nlm.nih.gov/pubmed/26106414
http://dx.doi.org/10.1155/2015/587893

Ejemplares similares